Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

Lenalidomide in combination with dexamethasone (Len‐dex) represents a highly effective treatment in relapsed/refractory multiple myeloma (RRMM) patients. However, an increased risk of secondary primary malignancies (SPMs), including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Cancer Med
Main Authors: Kotchetkov, Rouslan, Masih‐Khan, Esther, Chu, Chia‐Min, Atenafu, Eshetu G., Chen, Christine, Kukreti, Vishal, Trudel, Suzanne, Tiedemann, Rodger, Reece, Donna E.
Formáid: Artigo
Teanga:Inglês
Foilsithe: John Wiley and Sons Inc. 2016
Ábhair:
Clinical Cancer Research
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5269689/
https://ncbi.nlm.nih.gov/pubmed/27860411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.799
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla